Up-regulation of proBDNF/p75<sup>NTR</sup> signaling in antibody-secreting cells drives systemic lupus erythematosus.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35044824.
- Also identified by DOI 10.1126/sciadv.abj2797 and PMC identifier 8769540.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inappropriate expansion of antibody-secreting cells (ASCs) is typical of systemic lupus erythematosus (SLE), but the regulatory signaling of pathogenic ASCs is unclear. The present study shows that brain-derived neurotrophic factor precursor (proBDNF) and its high-affinity pan-75 neurotrophin receptor (p75<sup>NTR</sup>) are highly expressed in CD19<sup>+</sup>CD27<sup>hi</sup>CD38<sup>hi</sup> ASCs in patients with SLE and in CD19<sup>+</sup>CD44<sup>hi</sup>CD138<sup>+</sup> ASCs in lupus-like mice. The increased proBDNF<sup>+</sup> ASCs were positively correlated with clinical symptoms and higher titers of autoantibodies in SLE. Administration of monoclonal antibodies against proBDNF or specific knockout of p75<sup>NTR</sup> in CD19<sup>+</sup> B cells exerted a therapeutic effect on lupus mice by limiting the proportion of ASCs, reducing the production of autoantibodies and attenuating kidney injury. Blocking the biological function of proBDNF or p75<sup>NTR</sup> also inhibits ASC differentiation and antibody production in vitro. Together, these findings suggest that proBDNF-p75<sup>NTR</sup> signaling plays a critical pathogenic role in SLE through promoting ASC dysfunction.
Medical subject headings
- Lupus Erythematosus, Systemic
- Receptors, Nerve Growth Factor